Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12616000965404
Ethics application status
Approved
Date submitted
20/07/2016
Date registered
22/07/2016
Date last updated
12/06/2018
Type of registration
Retrospectively registered
Titles & IDs
Public title
Early pulmonary rehabilitation in people with mild Chronic Obstructive Pulmonary Disease (COPD)
Query!
Scientific title
Early pulmonary rehabilitation in people with mild Chronic Obstructive Pulmonary Disease (COPD)
Query!
Secondary ID [1]
289681
0
Nil Known
Query!
Universal Trial Number (UTN)
U1111-1185-5478
Query!
Trial acronym
EPR (Early Pulmonary Rehabilitation)
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease
299483
0
Query!
Condition category
Condition code
Respiratory
299462
299462
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Physical Medicine / Rehabilitation
299466
299466
0
0
Query!
Other physical medicine / rehabilitation
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Home-based pulmonary rehabilitation program (8 weeks): Participants are prescribed an exercise program by an experienced physiotherapist based on the results of their initial walking test. The exercise program consists of endurance (walking) and strengthening exercises. Participants are encouraged to exercise for 30 minutes, 5 times per week (including weekends). Strengthening exercises are performed using equipment that is available in the household (e.g. sit to stand from a chair, use of water bottles as arm weights). To optimise safety and a full understanding of the exercise program, an initial home visit from the physiotherapist is arranged before the program launch. The home visit talks one hour and 30 minutes on average. This home visit session facilitates exercise goal setting and demonstrates exercises. The physiotherapist helps participants to choose strengthening exercise provided by the Better Living for COPD handbook according to their physical abilities and equipment available in their household. The physiotherapist then prescribe the strengthening exercise types, sets and repetitions for the participant and record them using the exercise diary provided. Assessment and correction of inhaler use is also carried out during the home visit. Weekly phone calls is then undertaken by the physiotherapist to review the exercise diary, perform self-management training and promote exercise progression. Each weekly phone calls takes approximately 20 to 30 minutes. Disease specific self-management training and exercise progression is achieved using the principles of motivational interviewing. The aims of this training are to advance disease knowledge, promote problem solving and facilitate health behaviour change. A physiotherapist trained in the use of motivational interviewing is performing the telephone calls. Discussions of exercise goals settings, exercise tracking and recognition and treatment of acute exacerbation is provided in home exercise diaries which are kept over 8 weeks. Participants are encouraged to track their progress against their goals on a daily basis.
Home exercise diaries is delivered by the physiotherapist at the initial visit. Exercise diaries contains guidelines of identifying and managing moderate and severe exacerbation according to GOLD guidelines with an action plan, and contact details in case of emergencies. Following that, a goal setting sheet is provided to encourage goal setting at the start of every week with details about the time, location, and repetitions of exercises. A tracking sheet follows the goal setting sheet in order to help participants track their endurance and strengthening exercises daily.
Query!
Intervention code [1]
295304
0
Rehabilitation
Query!
Intervention code [2]
295307
0
Behaviour
Query!
Intervention code [3]
295308
0
Lifestyle
Query!
Comparator / control treatment
Usual care (8 week) comprise of an advice to exercise 5 times a week for 30 minutes each session. This advice is directed to them through the initial phone call with the physiotherapist. Participants also recieve weekly telephone calls form physiotherapists to discuss general health in order to control for attention. Each weekly phone calls takes approximately 10 to 20 minutes. Participants allocated to usual care do not receive any feedback regarding their exercise participation.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
298947
0
Exercise capacity measured by change in six minute walk distance
Query!
Assessment method [1]
298947
0
Query!
Timepoint [1]
298947
0
Baseline
8 weeks post commencement of the intervention
6 months post end-rehabilitation
Query!
Secondary outcome [1]
325732
0
Change in health related quality of life measured by Chronic Respiratory Disease Questionnaire domains of dyspnoea, fatigue, emotional function and mastery
Query!
Assessment method [1]
325732
0
Query!
Timepoint [1]
325732
0
Baseline
8 weeks post commencement of the intervention
6 months post end-rehabilitation
Query!
Secondary outcome [2]
325733
0
Change in physical activity variables measured objectively by the SenseWear Armband Accelerometer (SWA). The SWA is worn for 7 days each time point and posted back on the 8th day.
Query!
Assessment method [2]
325733
0
Query!
Timepoint [2]
325733
0
Baseline
8 weeks post commencement of the intervention
6 months post end-rehabilitation
Query!
Secondary outcome [3]
325734
0
Change in dyspnoea measured by the Modified Medical Research Council Scale
Query!
Assessment method [3]
325734
0
Query!
Timepoint [3]
325734
0
Baseline
8 weeks post commencement of the intervention
6 months post end-rehabilitation
Query!
Eligibility
Key inclusion criteria
1- Participants must be diagnosed with mild COPD (GOLD stage I), defined as FEV1/FVC < 0.7 and postbronchodilator FEV1 >= 80% predicted
2- Participants must be over 40 years old of age
3- Participants must have a smoking history of not less than 10 packet years (current or former smokers)
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1- Acute exacerbation or hospitalisations during the last month before recruiting
2- Having a primary diagnosis of any other respiratory related disease such as Asthma or Restrictive Lung Disease
3- Having comorbidities that prevents exercise participation
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation using computer-generated online software
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Block randomisation with stratification for site of recruitment.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
The mean improvement in 6MWD following traditional pulmonary rehabilitation in people with moderate to severe COPD is 48 metres, which represents a clinically important improvement. We anticipate that improvements in people with mild COPD will be at least as large. Assuming that the standard deviation of the change in 6MWD in mild COPD is 64 metres, a power of 0.8 and two-sided alpha of 0.0527, 58 participants (29 in each group) will be required to detect a difference in the change in 6MWD of 48 metres. The study will not be powered to detect differences in physical activity, symptoms or quality of life, but will provide preliminary data on which larger studies could be powered in the future.
Results will be expressed as mean and standard deviation (m +/- SD) values unless specified. Normality will be assessed using visual inspection and the Shapiro-Wilk test. All analysis will be performed using the SPSS software (version 22). Differences between group outcomes will be evaluated using a two-way analysis of variance (ANOVA) for continuous outcomes. The Chi-squared test will be used to evaluate the difference in categorical outcomes. A p-value of less than 0.05 will be considered to be significant.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2015
Query!
Date of last participant enrolment
Anticipated
31/10/2016
Query!
Actual
15/03/2017
Query!
Date of last data collection
Anticipated
15/11/2017
Query!
Actual
22/11/2017
Query!
Sample size
Target
58
Query!
Accrual to date
Query!
Final
58
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
6170
0
The Alfred - Prahran
Query!
Recruitment hospital [2]
6171
0
Austin Health - Austin Hospital - Heidelberg
Query!
Funding & Sponsors
Funding source category [1]
294063
0
Hospital
Query!
Name [1]
294063
0
Institution for Breathing and Sleep - The Austin Hospital
Query!
Address [1]
294063
0
Bowen Centre, Austin Hospital
145 Studley Road
Heidelberg
Victoria, 3084
Query!
Country [1]
294063
0
Australia
Query!
Funding source category [2]
294067
0
Charities/Societies/Foundations
Query!
Name [2]
294067
0
The Eirene Lucas Foundation
Query!
Address [2]
294067
0
Queen Street 31
3000 Melbourne
Victoria - Australia
Query!
Country [2]
294067
0
Australia
Query!
Primary sponsor type
University
Query!
Name
La Trobe University
Query!
Address
La Trobe Clinical School
Level4, the Alfred Centre
99 Commercial Road
Melbourne
VIC 3004
Query!
Country
Australia
Query!
Secondary sponsor category [1]
292891
0
None
Query!
Name [1]
292891
0
Query!
Address [1]
292891
0
Query!
Country [1]
292891
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
295478
0
The Alfred Hospital Ethics Committee
Query!
Ethics committee address [1]
295478
0
Office of ethics and research governance Ground floor, The Alfred 55 Commercial Road Melbourne VIC 3004
Query!
Ethics committee country [1]
295478
0
Australia
Query!
Date submitted for ethics approval [1]
295478
0
11/11/2014
Query!
Approval date [1]
295478
0
09/01/2015
Query!
Ethics approval number [1]
295478
0
101/15
Query!
Ethics committee name [2]
295479
0
The Austin Human Research Ethics Committee
Query!
Ethics committee address [2]
295479
0
Research Ethics Office for Research Level 8, Harold Stokes Building Austin Health PO Box 5555 Heidelberg Victoria Australia 3084
Query!
Ethics committee country [2]
295479
0
Australia
Query!
Date submitted for ethics approval [2]
295479
0
14/11/2014
Query!
Approval date [2]
295479
0
16/03/2015
Query!
Ethics approval number [2]
295479
0
HREC/14/Austin/599
Query!
Summary
Brief summary
Chronic obstructive pulmonary disease (COPD) is characterised by chronic inflammation of the airways and obstruction to airflow in the lungs, resulting in dyspnoea, chronic cough, and sputum production. The GOLD guidelines define mild COPD as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity ratio less than 0.7 and an FEV1 greater than of equal to 80% predicted. With COPD being a progressive and irreversible disease, disease management in the earlier stages is of great importance in order to optimise long term outcomes. People with mild COPD already have dynamic hyperinflation, impaired gas exchange and increased dead space ventilation which are associated with exercise limitation and fatigue. Also, a reduction in physical activity levels develops early in COPD, even before patients are diagnosed with the disease. According to a study exploring physical inactivity in patients with COPD, people with mild COPD were found to have 13% reduction in step counts and 47% reduction in time spent in moderate physical activity compared to healthy subjects. This is significant because lower physical activity levels are associated with increased mortality and increased hospitalisation in people with COPD. Pulmonary rehabilitation (PR) is an eight-week program involving exercise training, education and support. In our previous research, we developed a home-based model of PR for people with moderate to severe COPD. Our findings suggested promising results in improving physical activity levels and enhancing health related quality of life. People with even the mildest forms of COPD have been shown to have markedly reduced levels of physical activity. We believe that the benefits attained in our home based program for patients with more severe disease may also be achieved in people in the early-stages of COPD. As most individuals with early-stage COPD are managed in primary care (and many are still working), a home-based PR program may be more acceptable for this patient group. We hypothesise that a. pulmonary rehabilitation will result in clinically important improvement in six minute walk distance in people with GOLD stage I COPD; b. PR will improve dyspnoea, quality of life, and physical activity in GOLD stage I COPD. In this RCT we will recruit 58 people diagnosed with early stage, mild COPD according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. Participants will be randomised to receive either usual care or home-based pulmonary rehabilitation program. Clinical measures will be recorded at baseline, 8 weeks-time point and 6 months. Outcome measures will include exercise capacity using change in 6 minutes walk distance, physical activity levels objectively measured by the sense wear armband (SWA), health related quality of life measured by change in the Chronic Respiratory Questionnaire and change in dyspnoea measured by the Modified Research Council Scale.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
67426
0
Prof Anne Holland
Query!
Address
67426
0
La Trobe Clinical School
Level 4, The Alfred Centre
99 Commercial Road
MELBOURNE VIC 3004
Query!
Country
67426
0
Australia
Query!
Phone
67426
0
+61 419 379 821
Query!
Fax
67426
0
+61395332104
Query!
Email
67426
0
[email protected]
Query!
Contact person for public queries
Name
67427
0
Aroub Lahham
Query!
Address
67427
0
La Trobe Clinical School
Level 4, The Alfred Centre
99 Commercial Road
MELBOURNE VIC 3004
Query!
Country
67427
0
Australia
Query!
Phone
67427
0
+61 423 033 038
Query!
Fax
67427
0
+61395332104
Query!
Email
67427
0
[email protected]
Query!
Contact person for scientific queries
Name
67428
0
Anne Holland
Query!
Address
67428
0
La Trobe Clinical School
Level 4, The Alfred Centre
99 Commercial Road
MELBOURNE VIC 3004
Query!
Country
67428
0
Australia
Query!
Phone
67428
0
+61 419 379 821
Query!
Fax
67428
0
+61395332104
Query!
Email
67428
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
The impact of home-based pulmonary rehabilitation on people with mild chronic obstructive pulmonary disease: A randomised controlled trial.
2020
https://dx.doi.org/10.1111/crj.13138
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF